Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH
Designation highlights EFX's potential to treat NASH and its related comorbidities
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2020 -- (Healthcare Sales & Marketing Network) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatoh... Biopharmaceuticals, Mergers & Acquisitions Akero Therapeutics, non-alcoholic steatohepatitis, efruxifermin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Alcoholism | Cardiology | European Medicines Agency (EMA) | Heart | Marketing | Mergers and Aquisitions | Pharmaceuticals